NMOSD with anti-MOG antibodies following anti-TNFα therapy: A case report

Mult Scler Relat Disord. 2018 Nov:26:37-39. doi: 10.1016/j.msard.2018.08.029. Epub 2018 Aug 31.

Abstract

Tumor necrosis factor α (TNFα) inhibitors are highly effective and a therapeutic choice for several inflammatory diseases. Their broad and long-term use is associated with a growing number of paradoxical autoimmune events including demyelinating lesions of the central nervous system (CNS). We report and discuss a case of neuromyelitis optica spectrum disorder (NMOSD) with positive myelin oligodendrocyte glycoprotein antibodies (MOG-IgG1) following anti-TNFα therapy for a pustular psoriasis.

Keywords: Demyelinating lesions; MOG-IgG; NMOSD; TNFα blockers.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Inflammatory Agents / adverse effects*
  • Autoantibodies / immunology
  • Humans
  • Male
  • Myelin-Oligodendrocyte Glycoprotein / immunology*
  • Neuromyelitis Optica / diagnostic imaging
  • Neuromyelitis Optica / etiology*
  • Neuromyelitis Optica / immunology*
  • Neuromyelitis Optica / therapy
  • Psoriasis / drug therapy*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Anti-Inflammatory Agents
  • Autoantibodies
  • MOG protein, human
  • Myelin-Oligodendrocyte Glycoprotein
  • TNF protein, human
  • Tumor Necrosis Factor-alpha